Search clinical trials for: BG0002 (natalizumab)

Total 251 results

Biogen

Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) (STRATEGY)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals; United BioSource, LLC

Completed

JC-Virus (JCV) Antibody Program (STRATIFY-1)

Multiple Sclerosis

United States
Biogen

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Biogen

Completed

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke (ACTION2)

Acute Ischemic Stroke

Spain, United States, Germany, United Kingdom
Biogen

Completed

Clinical Disease Activity With Long Term Natalizumab Treatment

Relapsing-Remitting Multiple Sclerosis

Czechia, Belgium
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Biogen
Elan Pharmaceuticals

Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (TIMER)

Relapsing Remitting Multiple Sclerosis (RRMS)

Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Biogen

Completed

Ireland Natalizumab (TYSABRI) Observational Program (iTOP)

Relapsing-Remitting Multiple Sclerosis

Ireland
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
Biogen
Elan Pharmaceuticals

Completed

Natalizumab Re-Initiation of Dosing

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab (PROTYS)

Multiple Sclerosis

Switzerland
Biogen

Terminated

Natalizumab Subcutaneous Immunogenicity and Safety Study (SIMPLIFY)

Relapsing Multiple Sclerosis

Belgium
Biogen

Completed

Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

Multiple Sclerosis
Biogen

Terminated

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring (INFORM)

Crohn's Disease

United States, Puerto Rico
Biogen

Terminated

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (ESCALATE)

Relapsing Multiple Sclerosis

United States
Biogen

Completed

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke (ACTION)

Acute Ischemic Stroke

Spain, United States, Germany
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
Biogen

Completed

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (Tysabri Japan)

Multiple Sclerosis

Japan
Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
Biogen
Elan Pharmaceuticals

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

Natalizumab High Titer Immunogenicity and Safety

Multiple Sclerosis

United States
Biogen

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Japan
Biogen

Terminated

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel
Biogen

Completed

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (TYNERGY)

Fatigue | Relapsing-Remitting Multiple Sclerosis

Sweden, Norway, Austria, Denmark
Biogen

Completed

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Completed

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Progressive Multifocal Leukoencephalopathy

United States
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Biogen

Completed

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Relapsing-Remitting Multiple Sclerosis

Italy
Biogen

Terminated

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (REVEAL)

Relapsing-Remitting Multiple Sclerosis

United States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
Biogen

Completed

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

Multiple Sclerosis

United States
Techfields Pharma Co. Ltd

Withdrawn

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine

Pain, Back | Osteoarthritis of the Lumbar Spine
Biogen

Recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis

Spain, Ireland, United States, Germany
Biogen
Elan Pharmaceuticals

Withdrawn

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Crohn's Disease
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Crohn's Disease
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Completed

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Completed

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

Crohn's Disease

United States, United Kingdom
University at Buffalo

Completed

Natalizumab Temporary Discontinuation Study (NaTDS)

Multiple Sclerosis

United States
University Hospital, Caen
Biogen

Completed

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort (RELEVANT)

Multiple Sclerosis, Relapsing-Remitting

France
University of South Florida

Completed

The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (Tysex)

Multiple Sclerosis

United States
Cornerstone Health Care, PA
Biogen

Completed

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France
Biogen
Elan Pharmaceuticals

Completed

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Canada
Biogen

Completed

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Relapsing Forms of Multiple Sclerosis

United States

3

Subscribe